3 results
OX40 agonists have been shown to increase antitumor immunity and improve tumor-free survival in non-clinical models and OX40 agonist monoclonal antibodies (mAbs) are currently being evaluated in Phase I clinical trials. GSK3174998 is a humanized…
Primary ObjectiveThe primary objective is to show that fusion with the Valeo OL spacer produces similar improvement in MRDQ at all follow-up time points as compared to the same procedure with PEEK cages.Secondary ObjectivesTo show that the fusion…
To evaluate the safety and performance of the Paclitaxel Eluting Balloon Balloon mounted with a Cobalt Chromium stent (DEBS) and Paclitaxel Eluting Balloon (DEB) in patients with de novo coronary artery disease.